BeyondSpring Pharmaceuticals Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New York NY United States (2014)

Organization Overview

First Clinical Trial
2016
NCT02504489
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

BeyondSpring Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 3 Trials (5)

cyclophosphamide (cytoxan) (2 trials)

docetaxel (taxotere) (4 trials)

doxorubicin (Doxil) (2 trials)

Filgrastim (neupogen) (4 trials)

plinabulin (8 trials)

Drugs in Phase 2 Trials (1)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (1)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Neutropenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 7